Press Releases
May 25, 2023
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
March 23, 2023
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
November 7, 2022
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022
September 20, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159
Upcoming Events
June 2-6, 2023
ASCO 2023, Chicago, IL & Virtual
Pionyr Poster Presentation
July 18-20, 2023
Tumor Myeloid-Directed Therapies, Boston, MA
Pionyr Presentation
Past Events
November 8-12, 2022
SITC 2022, Boston, MA or Virtual
Pionyr Poster Presentation
October 4-6, 2022
Macrophage-Directed Therapies Summit, Boston, MA
Pionyr Presentations
June 15-16, 2022
Tumor Myeloid-Directed Therapies Summit, Boston, MA
Pionyr Presentation
March 20-24, 2022
Keystone Symposia - Cancer Immunotherapy, Whistler, Canada
Pionyr Presentation
November 10-14, 2021
SITC, Virtual & Washington, D.C.
Pionyr Poster Presentation
October 17-19, 2021
Pathology Visions, Virtual & Las Vegas, NV
Pionyr Poster Presentation
October 7-10, 2021
AACR-NCI-EORTC, Virtual
Pionyr Poster Presentation
October 8-9, 2021
8th Immunotherapy of Cancer Conference (ITOC8), Virtual
Pionyr Poster Presentation
Pionyr in the News
September 28, 2021
BioCentury / The TREM2 pipeline: Date Byte
April 8, 2021
BioCentury/ Macrophage therapies to watch at AACR
June 24, 2020
PharmaPhorum / Gilead to acquire half of cancer biotech Pionyr for $275m
June 24, 2020
PMLive / Gilead spends $275m on half-share in immuno-oncology firm Pionyr
June 23, 2020
San Francisco Business Times / With potential $1.8 billion deal, Gilead continues rollup of Bay Area cancer drug companies
